Biogen Inc.

BIIB | NASDAQ

Price Alert Chart Builder DCF Calculator

$225.32

+$6.25 (+2.85%)

Sep 22, 2026, 2:03 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
DGX Quest Diagnostics Incorporated	1.36%
DXCM DexCom	N/A
GMAB Genmab A/S	N/A
INCY Incyte	N/A
LH Labcorp	0.90%
PODD Insulet	N/A
STE STERIS plc	1.25%
TEVA Teva Pharmaceutical Industries	N/A
UTHR United Therapeutics	N/A
WAT Waters	N/A

Dividend Rankings ➞

Recent News

5 days ago / globenewswire.com
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
8 days ago / marketbeat.com
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
8 days ago / seekingalpha.com
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
13 days ago / seekingalpha.com
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
19 days ago / globenewswire.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
21 days ago / globenewswire.com
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
22 days ago / globenewswire.com
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
25 days ago / zacks.com
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
29 days ago / globenewswire.com
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
29 days ago / prnewswire.com
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease